116 Views | 49 Downloads
Correspondence: Anthony Mato, CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: matoa@mskcc.org
Author contributions: A.M., C.N., N.L., N.E.K., D.L.G., C.R.F., C.M.F., M.S.D., and J.P.S. recruited patients to the Registry; P.K. and A.S.S. completed the statistical analyses; and all authors interpreted the data, directed the development, review, and approval of this manuscript, and are fully responsible for all content and editorial decisions.
The authors thank all the patients and their families who participated in the Connect CLL Registry. The Connect CLL Scientific Steering Committee acknowledges the contributions of all past and current members of the committee for their guidance in the design of the Registry, and participation in analysis of the data, including:
Matthew S. Davids, Charles M. Farber, Ian Flinn, Christopher R. Flowers, David L. Grinblatt, Neil E. Kay, Michael Keating, Thomas J. Kipps, Mark F. Kozloff, Nicole Lamanna, Susan Lerner, Anthony Mato, Chadi Nabhan, Chris L. Pashos, Jeff P. Sharman, and Mark Weiss.
The Connect CLL Registry is sponsored and funded by Bristol-Myers Squibb. The sponsor supported the authors in collecting and analyzing the data reported in this Registry. The authors received medical writing support in the preparation of this manuscript from Victoria Edwards and Nicky Dekker of Excerpta Medica BV, supported by Bristol-Myers Squibb.
Disclosures: A.M. has been a consultant for AbbVie, Adaptive, AstraZeneca, Celgene Corporation (including data safety monitoring board), Genentech, Johnson & Johnson, LOXO, Regeneron, Pharmacyclics, Sunesis, and TG Therapeutics (including data safety monitoring board); and has received research funding from AbbVie, Acerta, Adaptive, DTRM, Genentech, Johnson & Johnson, Regeneron, LOXO, Pharmacyclics, Portola, and TG Therapeutics.
C.N. is employed by Aptitude Health.
N.L. has received research funding from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Infinity Pharma, Juno, Ming, ProNAi, and TG Therapeutics; been a consultant for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Juno, ProNAi, and Pharmacyclics; and served on an advisory committee for Celgene Corporation.
N.E.K. has received research funding from Gilead, Celgene Corporation, Hospira, Genentech, and Pharmacyclics and been on advisory committees for Gilead and Celgene Corporation.
D.L.G. has been a consultant and member of a speaker’s bureau for Celgene Corporation. C.R.F. has received research funding from Gilead, Spectrum, Millennium, Janssen, Infinity Pharma, AbbVie, Acerta, Pharmacyclics, and TG Therapeutics; served as a consultant for Celgene Corporation, OptumRx, Gilead, Seattle Genetics, Millennium, and Genentech/Roche; and received honoraria from Celgene Corporation.
C.M.F. has received research funding from Genentech and Gilead; been a consultant and part of a speaker’s bureau for Celgene Corporation, Gilead, Janssen, Pharmacyclics, Seattle Genetics, and Genentech; served on an advisory committee for Celgene Corporation; and received honoraria from Janssen.
M.S.D. has served as a consultant for AbbVie, Acerta Pharma, Adaptive Biotechnologies, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, and Verastem and received research funding from Acerta Pharma, Ascentage Pharma, Bristol-Myers Squibb, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem.
A.S.S., K.S., E.D.F., M.G., and P.K. are employees of Bristol-Myers Squibb and have equity. S.M.G.U. is a former employee of Celgene Corporation (now Bristol-Myers Squibb).
J.P.S. has received honoraria from Genentech, Gilead, and TG Therapeutics; been a consultant for Celgene Corporation, Genentech, Gilead, and Pharmacyclics; been a member of a speaker’s bureau for Gilead; received research funding from Celgene Corporation, Genentech, Gilead, Pharmacyclics, TG Therapeutics, Seattle Genetics, and Acerta; and received travel expenses from Celgene Corporation and Gilead.
None declared
© 2020 by The American Society of Hematology.